Coronavirus SARS-CoV-2

The spread of SARS-CoV-2 has become a serious challenge for public health, economy and social life in Europe and other regions of the world. To flatten the curve of new infections, not only social distancing and restrictions in public life but also fast and reliable testing plays an essential role.

As a leading provider of medical diagnostic services, SYNLAB is fulfilling its special responsibility in this challenging situation for the healthcare systems and the people in the various countries we are operating in. SYNLAB proactively partners with the competent authorities in order to support them with our medical expertise. We are leveraging our diagnostics capabilities to support countries in the fight against the coronavirus SARS-CoV-2.

 

Recent medical releases


Recent medical releases | SARS-CoV-2
  • Antibody monitoring allows to determine the amount of neutralizing anti-S1 specific antibodies which correlate with the human body’s level of protection against SARS-CoV-2
  • The amount of neutralizing anti-S1 specific antibodies continuously…
Read more
Recent medical releases | SARS-CoV-2
  • Through the worldwide spread of the SARS-CoV-2 virus, its RNA…
Read more
Recent medical releases | SARS-CoV-2

Medical data reveal that almost 40% of SARS-CoV-2 carriers can be missed by rapid antigen tests

  • New SYNLAB data confirm that almost 40% of cases tested positive for SARS-CoV-2 with PCR testing could have been missed when using rapid antigen tests.
  • A direct comparison between PCR and rapid…
Read more

Below you can find examples of SYNLAB's engagement across Europe and beyond highlighting the Group's contribution in the fight against the virus.


Recent medical releases | SARS-CoV-2
  • Antibody monitoring allows to determine the amount of neutralizing anti-S1 specific antibodies which correlate with the human body’s level of protection against SARS-CoV-2
  • The amount of neutralizing anti-S1 specific antibodies continuously…
Read more
SARS-CoV-2

Video report by RBB on the gargle test for the detection of…

 Read more
SARS-CoV-2

GERMANY: Researchers have virus mutations in focus

The coronavirus mutates 23 times. So far, variants from Brazil, Great Britain and South Africa have caused great concern. In order to localise them more quickly, more swabs have been examined for…

 Read more

SYNLAB has continuously expanded its testing capacity for SARS-CoV-2 and continues to expand it in order to best meet the growing demand. We are working very closely with our suppliers to ensure the continuity of our stocks. At the same time, we are constantly optimising the use of resources in our laboratory network in order to guarantee a maximum number of tests.

However, test capacities are not unlimited. It is therefore important that everybody adheres to the guidelines of public health authorities (such as WHO or Robert-Koch-Institute) as well as the official orders and guidelines of national governments and the European Union. On top of increasing our current testing capacity we are also engaged in developing the next generation of tests which would significantly improve the number of tests that can be done or provide quicker results.

We have 1,300 doctors and scientists fully engaged to ensure continuity of service, together with our patient facing employees, our laboratory technicians, logistics teams and our support functions. We are in a position to maintain our full offering of tests.  We have contingency and business continuity plans in place and are not only closely monitoring the dissemination of the virus but especially potential restrictions imposed by authorities. SYNLAB will take appropriate measures if necessary and depending on the individual situation in the countries we are operating in.

Share this page